Combining Eli Lilly's Taltz and Zepbound May Improve Psoriasis and Metabolic Benefits
An ongoing study suggests that combining Eli Lilly’s (LLY) psoriasis treatment, Taltz (ixekizumab), with its diabetes drug Zepbound (tirzepatide), may offer enhanced benefits for both skin conditions and metabolic health. The phase 3b TOGETHER-PsO trial is exploring the potential synergies of this combination therapy. Taltz, an IL-17 inhibitor used to treat moderate-to-severe plaque psoriasis, has shown efficacy in reducing inflammation. Zepbound, a GLP-1 receptor agonist approved for weight management and type 2 diabetes, also shows promise as part of broader treatment strategies. The combination could open new therapeutic avenues by addressing both dermatological and metabolic conditions simultaneously. This development highlights Eli Lilly’s efforts to expand the applications of its existing drug portfolio through innovative combinations.
Tickers: $LLY
Topics: Eli Lilly metabolic benefits psoriasis Taltz Zepbound